Document Detail


Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
MedLine Citation:
PMID:  20950346     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Schuller, S., Van Israël, N., Vanbelle, S., Clercx, C., McEntee, K. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. J. vet. Pharmacol. Therap. 34, 322-331. Aldosterone plays an important role in the pathophysiology of heart failure. Aldosterone receptor blockade has been shown to reduce morbidity and mortality in human patients with advanced congestive left ventricular heart failure. This study was designed to assess the efficacy and tolerance of long-term low-dose spironolactone when added to conventional heart failure treatment in dogs with advanced heart failure. Eighteen client-owned dogs with advanced congestive heart failure due to either degenerative valve disease (n = 11) or dilated cardiomyopathy (n = 7) were included in this prospective, placebo-controlled, double-blinded, randomized clinical study. After initial stabilization including furosemide, angiotensin-converting enzyme inhibitors, pimobendan and digoxin, spironolactone at a median dose of 0.52 mg/kg (range 0.49-0.8 mg/kg) once daily (n = 9) or placebo (n = 9) was added to the treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring, echocardiography, electrocardiogram, systolic blood pressure measurement, thoracic radiography, sodium, potassium, urea, creatinine, alanine aminotransferase, aldosterone and aminoterminal atrial natriuretic propeptide were assessed at baseline, 3 and 6 months. Survival times were not significantly different between the two treatment groups. Spironolactone was well tolerated when combined with conventional heart failure treatment.
Authors:
S Schuller; N VAN Israël; S Vanbelle; C Clercx; K McEntee
Related Documents :
8106896 - The role of angiotensin-converting enzyme inhibitors in reducing ventricular remodeling...
18806606 - Effect of l-2286, a poly(adp-ribose)polymerase inhibitor and enalapril on myocardial re...
17715446 - Understanding chronic heart failure.
22152956 - Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via...
8450156 - Reliability of quantitative coronary angiography of the target lesion immediately and 1...
19050596 - Comparative predictive value of infarct location, peak ck, and ejection fraction after ...
Publication Detail:
Type:  Journal Article     Date:  2010-10-14
Journal Detail:
Title:  Journal of veterinary pharmacology and therapeutics     Volume:  34     ISSN:  1365-2885     ISO Abbreviation:  J. Vet. Pharmacol. Ther.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910920     Medline TA:  J Vet Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  322-31     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Small Animal Clinical Studies, Faculty of Veterinary Medicine, University of Liège, Boulevard de Colonster, Liège, Belgium University College Dublin, University Veterinary Hospital, Belfield, Dublin, Ireland ACAPULCO Animal Cardiopulmonary Consultancy, Masta, Belgium Department of Biostatistics, University of Liège, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Akt phosphorylates Sec24: new clues into the regulation of ER-to-Golgi trafficking.
Next Document:  Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and t...